Hematology News and Research RSS Feed - Hematology News and Research

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Results from a study presented today at The International Liver Congress 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting. [More]
EKF launches next generation Hemo Control POC hemoglobin analyzer

EKF launches next generation Hemo Control POC hemoglobin analyzer

Available as a cost effective basic device which stores up to 4000 patient results, the new Hemo Control offers enhanced on-board Data Management (DM) functions following upgrade with the DM ‘add pack’ if required at a later date... [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
CML guidelines highlight need for TKI switch timing, choice

CML guidelines highlight need for TKI switch timing, choice

A review of the European LeukemiaNet guidelines on the care of patients with chronic myeloid leukaemia highlights the need for research into the timing and use of second-line and third-line tyrosine kinase inhibitors. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. [More]
UAB research findings may lead to better treatment for women with HER2+ breast cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year. [More]
Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%. [More]
Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas. [More]
Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient. [More]
Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Experts unveil strategic roadmap to advance treatments for people with lymphoma

Experts unveil strategic roadmap to advance treatments for people with lymphoma

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. [More]
Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. [More]
Patients with sickle cell disease have sleep disordered breathing problem

Patients with sickle cell disease have sleep disordered breathing problem

A new study in the Journal of Clinical Sleep Medicine revealed that 44 percent of adults with sickle cell disease who report trouble sleeping actually have a clinical diagnosis of sleep disordered breathing, including sleep apnea, which lowers their oxygen levels at night. [More]
Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer. [More]
2015 Minds Matter event raises funds to support brain tumor research

2015 Minds Matter event raises funds to support brain tumor research

One day in 2009, Maria Nijim's father got behind the wheel of his car and realized he couldn't see out of one eye. An MRI showed a tumor and then surgery confirmed a devastating diagnosis – glioblastoma – the most aggressive type of brain tumor. [More]
Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

A Spanish study suggests that bosutinib can help improve or maintain response in patients with chronic myeloid leukaemia after treatment failure of three previous tyrosine kinase inhibitors. [More]
Advertisement